DUBLIN--(BUSINESS WIRE)--The "Transdermal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

The publisher's Medical Devices sector report, "Transdermal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" provides comprehensive information about the Transdermal Drug Delivery pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Scope

• Extensive coverage of the Transdermal Drug Delivery under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Transdermal Drug Delivery and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Transdermal Drug Delivery under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

2 Introduction

2.1 Transdermal Drug Delivery Overview

3 Products under Development

3.1 Transdermal Drug Delivery - Pipeline Products by Stage of Development

3.2 Transdermal Drug Delivery - Pipeline Products by Segment

3.3 Transdermal Drug Delivery - Pipeline Products by Territory

3.4 Transdermal Drug Delivery - Pipeline Products by Regulatory Path

3.5 Transdermal Drug Delivery - Pipeline Products by Estimated Approval Date

3.6 Transdermal Drug Delivery - Ongoing Clinical Trials

4 Transdermal Drug Delivery - Pipeline Products under Development by Companies

4.1 Transdermal Drug Delivery Companies - Pipeline Products by Stage of Development

4.2 Transdermal Drug Delivery - Pipeline Products by Stage of Development

5 Transdermal Drug Delivery Companies and Product Overview

6 Transdermal Drug Delivery- Recent Developments

7 Appendix

Companies Mentioned

• 4P Therapeutics LLC
• Actuated Medical Inc
• Adynxx Inc
• Aequus Pharmaceuticals Inc
• AerMedX Ltd
• Agile Therapeutics Inc
• Allergan Ltd
• American Chemical Society
• AMW GmbH
• Apogee Technology Inc
• Asahi Kasei Pharma Corp
• ASCIL Biopharm
• Avecho Biotechnology Ltd
• Avro Life Sciences
• Boryung Pharmaceutical Co Ltd
• Burke Pharmaceuticals LLC
• Candesant Biomedical Inc
• Cassava Sciences Inc
• CB Scientific Inc
• Cerimon Pharmaceuticals, Inc. (Inactive)
• Chrono Therapeutics Inc
• Cipla Ltd
• Clexio Biosciences Ltd
• Corium Inc
• Daewoong Pharmaceutical Co Ltd
• DBV Technologies SA
• DD Therapeutics LLC
• Delpor Inc
• Dermisonics Inc
• Dharma Therapeutics, Inc. (Inactive)
• Diomics Corp
• Drexel University
• Drug Delivery Co LLC
• DURECT Corp
• Echo Therapeutics Inc
• Emplicure AB
• Endo International Plc
• Endomimetics LLC
• Extend Biosciences Inc
• Fe3 Medical Inc
• Futura Medical Plc
• Georgia Institute of Technology
• Georgia State University
• GlobeStar Therapeutics Corp
• Hisamitsu Pharmaceutical Co Inc
• I M Sechenov Moscow State Medical University
• Icure Pharmaceutical Inc
• ImmunoMatrix LLC
• ImmuPatch
• Indian Institute of Science
• Indian Institute of Technology Bombay
• Indian Institute of Technology Hyderabad
• InMed Pharmaceuticals Inc
• Institute of Materials Research & Engineering
• Intercell AG (Inactive)
• Interstitial NS
• Isis Biopolymer Inc (Inactive)
• Janisys
• Jiaxing Xinwen Biotechnology Co Ltd
• Jubilee Biotech
• Kailian Medical Technology Co Ltd
• Karolinska Institute
• Kindeva Drug Delivery LP
• KTH Royal Institute of Technology
• Leo Pharma AS
• Livzon Pharmaceutical Group Co Ltd
• Lohmann Therapie-Systeme AG
• Luye Pharma Group Ltd
• Massachusetts Institute of Technology
• Mayne Pharma Group Ltd
• Medherant Ltd
• MEDRx Co Ltd
• MedRx, Inc.
• Microdermics Inc
• Micron Biomedical Inc
• Micropoint Technologies Pte Ltd
• Mineed Technology Co Ltd
• mPhase Technologies Inc
• Mycrodose Therapeutics Inc
• MyLife Technologies
• Nanyang Technological University
• National Dental Centre Singapore
• National University of Singapore
• Nemaura Pharma Ltd
• NeuroDerm Ltd
• Nitto Denko Corp
• North Carolina State University
• Noven Pharmaceuticals Inc
• NutriBand Inc
• Nuvo Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd
• Texas Tech University
• The Sheikh Zayed Institute for Pediatric Surgical Innovation
• TheraJect Inc
• TheraSolve NV (Inactive)
• Theratech, Inc.
• Theris Medical Inc
• Thrudermic LLC
• Titan Pharmaceuticals Inc
• Toa Eiyo Ltd
• Transcu Group Limited (Inactive)
• Transdermal Delivery Solutions Corp
• TransPharma Medical Ltd (Inactive)
• Transport Pharmaceuticals Inc
• University of Helsinki
• University of Illinois at Chicago
• University of South Florida
• University of Tokyo
• University of Toronto
• University of Washington
• Vaxess Technologies Inc
• Vaxxas Pty Ltd
• Verndari Inc
• ViiV Healthcare UK Ltd
• Virpax Pharmaceuticals Inc
• Vyteris, Inc. (Inactive)
• Wellfully Ltd
• Xel Pharmaceuticals Inc
• XPhyto Therapeutics Corp
• Zambon Italia Srl
• Z-Cube Srl
• ZetrOZ Inc
• Zosano Pharma Corp
• Zylo Therapeutics LLC
• Zynerba Pharmaceuticals Inc

For more information about this report visit

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900